Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memgen, Inc.
DEKA Biosciences
Exelixis
Purple Biotech Ltd.
Eli Lilly and Company
Fate Therapeutics
Gritstone bio, Inc.
Tempest Therapeutics
Fate Therapeutics
Five Prime Therapeutics, Inc.
Bristol-Myers Squibb
Celgene
Western Regional Medical Center